From Research to Real-world Impact: How Meril’s journey of adding more to life in 2024 will lead forward in 2025
As we approach the end of 2024, it is essential to put the year in review and amalgamate the milestones which have anchored to Meril Life Sciences' journey of transforming tomorrow. Each accomplishment serves as an account of MerilS overarching commitment to scientific progress for the uplifting of human health. But what lies ahead? how do this yearS initiations and achievements put the prognosticated impacts on the healthcare landscape of 2025 within perspective?
The Launch of the MISSO Robotic System
A pivotal moment in MerilS narrative this year was the launch of the MISSO Robotic System, a cutting-edge orthopedic robot that brings surgical precision to life. MISSO, a sophisticated system that integrates advanced robotics with intuitive design and a robust AI-enabled software, allows for minimally invasive procedures that expedite recovery times and significantly improve patient outcomes. India has witnessed a significant increase in joint replacement surgeries over the years, with hip replacements on the rise, projected to grow at the highest rate globally from 2020 to 2026*. Given the staggering rise in population - the percentage which comprises of elderly people in India is estimated at about 10.5%, among whom the burden of orthopedic disease is more prevalent creating a prominent clinical need that is currently underserved in many regions of the country and so is the availability of modern orthopedic treatment modalities. The MISSO robotic system, equipped with a salient CT based approach and state-of-the art AI-enabled precision is set to assist surgeons on an advanced scale, augmenting clinical outcomes thoroughly and ensuring more people have access to life-enhancing robotic-assisted arthroplasty procedures while spearheading global advancements; MISSO is setting new benchmarks in surgical excellence.
The Landmark Randomised Controlled Trial published in the Lancet
Equally noteworthy was the results from the LANDMARK Randomized Controlled Trial, which demonstrated that
the Myval THV (Transcatheter Heart Valve) series is non-inferior to contemporary market alternatives, the finding
was presented at EuroPCR 2024. The subsequent publication of these results in the esteemed journal, The
Lancet marks a pivotal moment for the field of cardiovascular research. Randomized controlled trials (RCTs) play
a crucial role in clinical research by providing reliable evidence regarding the efficacy and safety of newer
interventions. They minimize bias through randomization, ensuring that participant characteristics are balanced
across treatment and control groups. This allows researchers to attribute differences in outcomes directly to the
intervention being tested, rather than to confounding variables. Specifically, the non-inferiority trial demonstrates
that the Myval THV series is at par with an existing standard of care. This trial has significant implications for
everyday clinical practice in the upcoming years, indicating effectiveness fortifying Meril’s commitment to
evidence-based healthcare solutions, reliability and adherence to the highest of quality standards. This major
late-breaking trial echoes MerilS disposition for vigorous clinical research that translates into benevolent patient
outcomes for the global landscape of cardiovascular medicine, assisting healthcare professionals with solutions
that derive dependable and favorable results.
Inauguration of the State-of-the-Art Manufacturing Facility in Vapi, Gujarat
The inauguration of MerilS state-of-the-art manufacturing facility under the Production Linked Incentive (PLI)
scheme marked another significant achievement this year. Virtually inaugurated by Prime Minister Shri Narendra
Modi, this facility, housing a diverse cohort of research and development personnel - is poised to enhance
production capabilities while ensuring adherence to international quality standards. This strategic investment
toward upholding a strong infrastructural foundation exemplifies Meril’s vision to scale operations on a much
larger order of magnitude and depicts India’s growing excellence in the healthcare sector. A staunch commitment
to research and technological development backed by rigorous clinical methodologies underpins MerilS broader
goal of self-reliance and efficiency and in the years to come, the production linked incentive scheme encourages
prospective verticals and newer developments across MerilS manufacturing portfolio.
Meril Academy makes itS way to new global locations, building a larger ecosystem of learning
Education remains a cornerstone of MerilS mission, and 2024 saw the impressive expansion of Meril Academy both nationally and internationally. With new branches established in Kochi and Delhi, alongside an international presence in Spain, Germany, Turkey and Russia - Meril Academy continues to add to the learning curves of healthcare professionals through comprehensive scientific programs and offers a platform for global knowledge exchange which augments the practice of medicine within the healthcare community and builds a database for progress in 2025.
Characterized by the guiding principle of "Adding More to Life," Meril continues to move forward on the trajectory
of positive transformations, we remain resolute in our purpose of deriving the best possible outcomes for patients,
ensuring that every step we take reflects our dedication to quality, efficacy, and excellence.
Renewing our core belief of alleviating suffering and contributing to the well-being of patients worldwide, we reflect
on the past year with immense gratitude. As we look to the future, we are inspired by the possibilities ahead and
remain steadfast in our mission to catalyze new breakthroughs and developments that will shape the landscape of
healthcare for years to come.
*https://pmc.ncbi.nlm.nih.gov/articles/PMC8149501
